The evolution of risk factors for respiratory syncytial virus-related hospitalisation in infants born at 32-35 weeks' gestational age: time-based analysis using data from the FLIP-2 study

被引:13
|
作者
Carbonell, Xavier [1 ]
Fullarton, John R. [2 ]
Gooch, Katherine L. [3 ]
Figueras-Aloy, Jose [4 ]
机构
[1] Hosp Clin Barcelona, Serv Neonatol, Barcelona, Spain
[2] Strategen Ltd, Basingstoke, Hants, England
[3] Abbott Labs, Chicago, IL USA
[4] Hosp Clin Seu Maternitat, Serv Neonatol, Barcelona, Spain
关键词
Infant; patient admission; premature; respiratory syncytial viruses; risk factors; INFECTION REQUIRING HOSPITALIZATION; 35 COMPLETED WEEKS; PREMATURE-INFANTS; BRONCHIOLITIS; ASTHMA; ALLERGY; MORBIDITY; CHILDREN; WHEEZE;
D O I
10.1515/jpm-2011-0248
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Aim: The aim of this study was to examine whether the risk for respiratory syncytial virus (RSV)-related hospitalisation changes through the first year of life in infants of 32-35 weeks' gestational age (wGA). Methods: Risk factors from the FLIP-2 study (190 cases/4566 age-matched controls) were included in a Cox regression analysis wherein time slices were taken at 1-month intervals from birth. Results: Half of all RSV hospitalisations occurred in the first 68 days after birth, with 56% occurring within 90 days. The time taken for 50% of hospitalisations to occur was 148 days for those born outside the RSV season and 58 days for those born within the season. By 90 days old, 84% of infants born in the season and 20% of those born outside the season were hospitalised. In both groups, hospitalisations occurred >= 5 months after birth. Male sex, smoking whilst pregnant, month of birth, duration of breastfeeding, number of siblings at school, and number of smokers in household all contributed to the risk of RSV hospitalisation beyond the age of 90 days. Conclusions: The risk of RSV hospitalisation appears to persist to at least 5-6 months old in 32-35 wGA infants, which has implications for the optimal management of disease prevention.
引用
下载
收藏
页码:685 / 691
页数:7
相关论文
共 18 条
  • [11] Impact of the risk scoring model on the cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks in Canada
    Lanctot, K. L.
    Paes, B.
    Francis, P. L.
    Chiu, A.
    Hui, C.
    Oh, P., I
    VALUE IN HEALTH, 2008, 11 (03) : A248 - A249
  • [12] Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis
    Robinson, Joan L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (07) : 1631 - 1632
  • [13] Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis Reply
    Lanctot, Krista L.
    Paes, Bosco
    Hui, Charles
    Chiu, Aaron
    Tarride, Jean-Eric
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (07) : 1632 - 1633
  • [14] European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian data
    Simoes, Eric A. F.
    Carbonell-Estrany, Xavier
    Fullarton, John R.
    Rossi, Giovanni A.
    Barberi, Ignazio
    Lanari, Marcello
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2011, 24 (01): : 152 - 157
  • [15] The influence of birth weight amongst 33-35 weeks gestational age (wGA) infants on the risk of respiratory syncytial virus (RSV) hospitalisation: a pooled analysis
    Carbonell-Estrany, Xavier
    Fullarton, John R.
    Gooch, Katherine L.
    Gouyon, Jean-Bernard
    Lanari, Marcello
    Rodgers-Gray, Barry S.
    Thwaites, Richard J.
    Vo, Pamela G.
    Liese, Johannes G.
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2017, 30 (02): : 134 - 140
  • [16] Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain
    Figueras-Aloy, J
    Carbonell-Estrany, X
    Quero, J
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (09) : 815 - 820
  • [17] Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec A Multicenter Retrospective Study
    Papenburg, Jesse
    Saleem, Mahwesh
    Teselink, Johannes
    Li, Abby
    Caouette, Georges
    Masse, Edith
    Lanctot, Krista L.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2020, 39 (08) : 694 - 699
  • [18] A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age
    Keary, Ian P.
    Ravasio, Roberto
    Fullarton, John R.
    Manzoni, Paolo
    Lanari, Marcello
    Paes, Bosco A.
    Carbonell-Estrany, Xavier
    Baraldi, Eugenio
    Tarride, Jean-Eric
    Rodgers-Gray, Barry
    PLOS ONE, 2023, 18 (08):